
1. clin vaccine immunol. 2016 jan 27;23(3):186-8. doi: 10.1128/cvi.00037-16.

progress toward respiratory syncytial virus vaccine.

neuzil km(1).

author information: 
(1)department medicine pediatrics, center vaccine development,
university maryland school medicine, baltimore, maryland, usa
kneuzil@medicine.umaryland.edu.

comment on
    clin vaccine immunol. 2016 mar;23(3):243-5.
    clin vaccine immunol. 2016 mar;23(3):189-95.

in accompanying papers (p. l. acosta, m. t. caballero, f. p. polack, clin
vaccine immunol 23:189-195, 2016, http://dx.doi.org/10.1128/cvi.00609-15; m.
vissers, i. m. l. ahout, m. i. de jonge, g. ferwerda, clin vaccine immunol
23:243-245, 2016, http://dx.doi.org/10.1128/cvi.00590-15) issue of
clinical vaccine immunology, history immune mechanisms underlying 
vaccine-enhanced respiratory syncytial virus (rsv) disease investigations 
of mucosal antibodies association viral load rsv-infected
children, respectively, described. commentary discusses rsv vaccine
candidates, target populations, challenges associated achieving a
safe effective vaccine.

copyright Â© 2016, american society microbiology. rights reserved.

doi: 10.1128/cvi.00037-16 
pmcid: pmc4783429
pmid: 26818954  [indexed medline]

